HOME ABOUT CONTACT AVAILABLE ISSUES SUBSCRIBE MEDIA & ADS
LATEST UPDATES » Vol 22, No 11, November 2018 – The Asian Cancer - War on liver cancer       » 2018 Nobel Prize in Physiology or Medicine winners       » Women more prone to selected chemotherapy side effects       » Tibetan fungus could help fight liver cancer       » Standards for TCM decoction to be applied globally       » RMB200 million donation to build Tsinghua University Biomedical Sciences Building      
INSIDE INDUSTRY
SGD34 million initiative to boost pharma manufacturing industry
A*STAR leads initiative with pharma giants and universities to boost manufacturing innovations and speedier production

To drive the transformation of Singapore’s pharmaceutical manufacturing industry and pre-position it for the future economy, the Agency for Science, Technology and Research (A*STAR) has initiated the Pharma Innovation Programme Singapore (PIPS) in partnership with the National University of Singapore (NUS); the Nanyang Technological University (NTU Singapore); the Singapore Institute of Technology (SIT); and leading pharma companies GlaxoSmithKline (GSK), MSD International GmbH (Singapore Branch), and Pfizer Asia Pacific Pte Ltd.

The members of PIPS inked a consortium agreement valued at SGD34 million on 16 October 2018 at the Industrial Transformation Asia-Pacific trade show.

The pharmaceutical manufacturing industry currently contributes over 3 percent to Singapore’s GDP. Eight of the top 10 pharmaceutical companies in the world have facilities in Singapore, and four of the top 10 drugs by global revenue are manufactured here. Since 2000, the sector’s manufacturing output today has grown by more than 3 times.

However, globally the sector is facing sustained pressures on drug pricing, changing expectations of payors, and mounting competition in emerging markets. It is critical for pharmaceutical manufacturing to look at increasing productivity and operational efficiency through leveraging advances in manufacturing technologies and data analytics.

The PIPS consortium will therefore focus on areas such as continuous manufacturing, bio-catalysis, advanced process control and process analytical technology, digitalisation, and enhanced pharmaceutical operations.

The aim is to raise the bar of pharma manufacturing, including more sustainable manufacturing processes and the speedier production of active pharmaceutical ingredients, which will allow drugs to reach patients’ bedsides quicker.

Click here for the complete issue.

NEWS CRUNCH  
news Asia is the fastest growing region for nutraceuticals
news 2018 Nobel Prize in Physiology or Medicine winners
news Vitafoods Asia expands by 40 per cent in 2018
PR NEWSWIRE  
Asia Pacific Biotech News
EDITORS' CHOICE  
COLUMNS  

APBN Editorial Calendar 2018
January:
Obesity / Outlook for 2018
February:
Searching for the fountain of youth
March:
Women in Science - Making a difference
April:
Digestive health in the 21st century - Trust your guts
May:
Dental health - The root to good health
June:
Cancer - Therapies and strategies for better patient outcomes
July:
Water management - Technologies for biotech and pharmaceutical industries
August:
Regenerative technology - Meat of the future
September:
Doctor Robot - The digital healthcare revolution
October:
Bones / Breast cancer
November:
Liver health / Top science research nations & institutions
December:
AIDS / Breakthrough of the year/Emerging trends
Editorial calendar is subjected to changes.
MAGAZINE TAGS
About Us
Events
Available issues
Editorial Board
Letters to Editor
Instructions to Authors
Advertise with Us
CONTACT
World Scientific Publishing Co. Pte. Ltd.
5 Toh Tuck Link, Singapore 596224
Tel: 65-6466-5775
Fax: 65-6467-7667
» For Editorial Enquiries:
   biotech_edit@wspc.com or Ms Lim Guan Yu
» For Subscriptions, Advertisements &
   Media Partnerships Enquiries:
   biotech_ad@wspc.com
Copyright© 2018 World Scientific Publishing Co Pte Ltd  •  Privacy Policy